Effect of novel oral anticoagulants on coagulation tests
| Novel oral anticoagulant . | PT . | aPTT . | Thrombin clotting time . | Ecarin clotting time . | Hemoclot assay . | Anti–factor Xa activity . | |
|---|---|---|---|---|---|---|---|
| Clot based . | Chromogenic . | ||||||
| Dabigatran | ↑ or ↔ | ↑ | ↑ | ↑ | ↑* | — | — |
| Rivaroxaban | ↑ or ↔ | ↑ or ↔ | — | — | — | ↑ | ↑* |
| Apixaban | ↑ or ↔ | ↑ or ↔ | — | — | — | ↑* | ↑* |
| Novel oral anticoagulant . | PT . | aPTT . | Thrombin clotting time . | Ecarin clotting time . | Hemoclot assay . | Anti–factor Xa activity . | |
|---|---|---|---|---|---|---|---|
| Clot based . | Chromogenic . | ||||||
| Dabigatran | ↑ or ↔ | ↑ | ↑ | ↑ | ↑* | — | — |
| Rivaroxaban | ↑ or ↔ | ↑ or ↔ | — | — | — | ↑ | ↑* |
| Apixaban | ↑ or ↔ | ↑ or ↔ | — | — | — | ↑* | ↑* |
Preferred test. Adapted from previously published review articles.1,2,34
↑, simple increase; ↔, no change; —, not applicable.